How to buy Arbutus Biopharma Corporation stock | $4.14

Arbutus Biopharma Corporation is a biotechnology business based in the US. Arbutus Biopharma Corporation shares (ABUS) are listed on the NASDAQ and all prices are listed in US Dollars. Arbutus Biopharma Corporation employs 76 staff and has a trailing 12-month revenue of around 0.00.

Arbutus Biopharma Corporation stock price (NASDAQ: ABUS)

Use our graph to track the performance of ABUS stocks over time.

Arbutus Biopharma Corporation shares at a glance

• Key figures

Information last updated 2021-10-16.

Latest market close	$4.14
52-week range	$2.43 - $5.14
50-day moving average	$4.06
200-day moving average	$3.29
Wall St. target price	$6.00
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-0.95

Buy Arbutus Biopharma Corporation shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Arbutus Biopharma Corporation stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Arbutus Biopharma Corporation price performance over time

Historical closes compared with the close of $4.14 from 2021-10-18

1 week (2021-10-09)	N/A
1 month (2021-09-20)	-3.50%
3 months (2021-07-20)	52.21%
6 months (2021-04-20)	38.46%

1 year (2020-10-20)	43.75%
2 years (2019-10-18)	346.51%
3 years (2018-10-19)	4.34
5 years (2016-10-20)	34.42%

Arbutus Biopharma Corporation financials

Revenue TTM	$8.4 million
Gross profit TTM	$-40,567,000
Return on assets TTM	-34.75%
Return on equity TTM	-86.05%
Profit margin	0%
Book value	$1.03
Market capitalisation	$404.6 million

TTM: trailing 12 months

Shorting Arbutus Biopharma Corporation shares

There are currently 2.8 million Arbutus Biopharma Corporation shares held short by investors – that's known as Arbutus Biopharma Corporation's "short interest". This figure is 24.8% down from 3.7 million last month.

There are a few different ways that this level of interest in shorting Arbutus Biopharma Corporation shares can be evaluated.

Arbutus Biopharma Corporation's "short interest ratio" (SIR)

Arbutus Biopharma Corporation's "short interest ratio" (SIR) is the quantity of Arbutus Biopharma Corporation shares currently shorted divided by the average quantity of Arbutus Biopharma Corporation shares traded daily (recently around 3.5 million). Arbutus Biopharma Corporation's SIR currently stands at 0.8. In other words for every 100,000 Arbutus Biopharma Corporation shares traded daily on the market, roughly 800 shares are currently held short.

However Arbutus Biopharma Corporation's short interest can also be evaluated against the total number of Arbutus Biopharma Corporation shares, or, against the total number of tradable Arbutus Biopharma Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Arbutus Biopharma Corporation's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Arbutus Biopharma Corporation shares in existence, roughly 30 shares are currently held short) or 0.0376% of the tradable shares (for every 100,000 tradable Arbutus Biopharma Corporation shares, roughly 38 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Arbutus Biopharma Corporation.

Find out more about how you can short Arbutus Biopharma Corporation stock.

Arbutus Biopharma Corporation share dividends

We're not expecting Arbutus Biopharma Corporation to pay a dividend over the next 12 months.

Have Arbutus Biopharma Corporation's shares ever split?

Arbutus Biopharma Corporation's shares were split on a 1:5 basis on 3 November 2010. So if you had owned 5 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Arbutus Biopharma Corporation shares – just the quantity. However, indirectly, the new 400% higher share price could have impacted the market appetite for Arbutus Biopharma Corporation shares which in turn could have impacted Arbutus Biopharma Corporation's share price.

Arbutus Biopharma Corporation share price volatility

Over the last 12 months, Arbutus Biopharma Corporation's shares have ranged in value from as little as $2.43 up to $5.14. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Arbutus Biopharma Corporation's is 2.682. This would suggest that Arbutus Biopharma Corporation's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Arbutus Biopharma Corporation overview

Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously-delivered RNA interference product candidate, which in an ongoing Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated GalNAc delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include HBV RNA destabilizers, an orally active agent to destabilize HBV RNA, which leads to RNA degradation and to reduction in HBV proteins; oral PD-L1 inhibitor to enable reawakening patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Marqibo; Gritstone Oncology, Inc. ; Alnylam Pharmaceuticals, Inc. ; Acuitas Therapeutics, Inc. ; and Antios Therapeutics, Inc.

Frequently asked questions

What percentage of Arbutus Biopharma Corporation is owned by insiders or institutions?
Currently 19.153% of Arbutus Biopharma Corporation shares are held by insiders and 29.796% by institutions. How many people work for Arbutus Biopharma Corporation?
Latest data suggests 76 work at Arbutus Biopharma Corporation. When does the fiscal year end for Arbutus Biopharma Corporation?
Arbutus Biopharma Corporation's fiscal year ends in December. Where is Arbutus Biopharma Corporation based?
Arbutus Biopharma Corporation's address is: 701 Veterans Circle, Warminster, PA, United States, 18974 What is Arbutus Biopharma Corporation's ISIN number?
Arbutus Biopharma Corporation's international securities identification number is: CA03879J1003 What is Arbutus Biopharma Corporation's CUSIP number?
Arbutus Biopharma Corporation's Committee on Uniform Securities Identification Procedures number is: 03879J100